Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome | MicrobiomeTrials← Back to trialsNCT07654114
Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-05-21Est. Completion: 2027-05
Enrollment target: 30 participants Locations- Hospital del Mar Medical Research Institute, Barcelona, Barcelona, Spain
- Consorci Corporació Sanitaria Parc Taulí. Institut Investigació i Innovació Parc Taulí (I3PT), Sabadell, Barcelona, Spain
Other microbiome trials you might be interested in
Neurodevelopmental DisordersAutismAutism Spectrum DisorderFragile X SyndromeTuberous Sclerosis22Q11 Deletion Syndrome22Q11 DeletionADHDTic DisordersTourette SyndromeTourette Syndrome in ChildrenTourette Syndrome in AdolescenceADHD - Combined TypeADHD Predominantly Inattentive TypeADHD, Predominantly Hyperactive - ImpulsiveAnxietyAnxiety Disorders
There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental d…
Calgary, CanadaEst. completion Sep 2027
Fragile X Syndrome
This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of…
Phoenix, United StatesEst. completion Oct 2027